Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Fiona-and-Stanley-Druckenmiller-Center-for-Lung-Cancer-Research"

1 News Found

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
Diagnostic Center | September 09, 2024

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients